论文部分内容阅读
目的探讨胸腔积液中肿瘤标记物癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、神经特异性烯醇化酶(NSE)联合检测对肺癌及其病期诊断的应用价值。方法采用化学发光法对49例肺癌患者的胸水及31例非肺癌患者的胸水进行免疫蛋白定量分析。结果肺癌组CEA、CYFRA2121和NSE水平明显高于其他非肺癌疾病组;非小细胞肺癌患者胸腔积液中CEA、CYFRA21-1含量显著高于其他肿瘤组及小细胞肺癌组(P<0.01),其中CYFRA21-1在鳞癌最高,CEA在腺癌最高;而小细胞肺癌NSE显著高于非小细胞肺癌组及其他非肺癌组(P<0.01)。并且三项指标的数值分别随肺癌分期的增高而增高。结论胸腔积液CEA、CYFRA21-1、NSE联合检测对诊断肺癌有重要意义,同时对肺癌临床分期的判断有较高的应用价值。
Objective To investigate the diagnostic value of combined detection of carcinoembryonic antigen (CEA), cytokeratin 19 (CYFRA21-1) and neuroendocrine enolase (NSE) in pleural effusion for the diagnosis of lung cancer and its stage. Methods Chemiluminescence was used to quantify pleural effusion in pleural effusion of 49 patients with lung cancer and 31 patients with non-lung cancer. Results The levels of CEA, CYFRA2121 and NSE in lung cancer patients were significantly higher than those in other non-lung cancer patients. The levels of CEA and CYFRA21-1 in pleural effusion of patients with non-small cell lung cancer were significantly higher than those in other cancer patients and small cell lung cancer patients (P <0.01) Among them, CYFRA21-1 was the highest in squamous cell carcinomas and CEA was the highest in adenocarcinomas, while NSE in small cell lung cancer was significantly higher than that in non-small cell lung cancer and other non-lung cancer groups (P <0.01). And the value of the three indicators increased with the staging of lung cancer increased. Conclusions The combined detection of CEA, CYFRA21-1 and NSE in pleural effusion is of great significance for the diagnosis of lung cancer, meanwhile, it is of high value in judging the clinical stage of lung cancer.